Article: Acute Illness and Death in Children With Adrenal Insufficiency
A recently published article from Royal Manchester Children’s Hospital, the University of Manchester, and Manchester Royal Infirmary concludes that “during intercurrent illness episodes, parents reliably increased oral hydrocortisone doses but rarely administered emergency intramuscular hydrocortisone”. The study “highlights the need for improved patient/parent education and training to reduce the risk of serious consequences in a choice of usable formats including alternative strategies” and “did not identify any demographic risk factors for either AC or AD, but this requires further exploration in larger cohorts.”.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...